Drug intelligence / Profile preview

sindrelimab

Development stage: Unknown
Lead developer: Innovent Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Sindrelimab is a monoclonal antibody developed as an immune checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) receptor. By binding to PD-1, it blocks the interaction with its ligands (PD-L1 and PD-L2), thereby enhancing T-cell mediated immune responses against tumor cells. Sindrelimab is being investigated primarily for the treatment of various cancers, including non-small cell lung cancer and other solid tumors. It is part of a class of immunotherapies designed to overcome tumor-induced immune suppression.

Other names: sindrelimab

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on sindrelimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sindrelimab.

Explore the full profile